Imatinib (Gleevec®) as a paradigm of targeted cancer therapies

Research output: Contribution to journalArticle

5 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)1-3
Number of pages3
JournalKeio Journal of Medicine
Volume59
Issue number1
DOIs
StatePublished - Mar 2010

Fingerprint

21st Century History
19th Century History
20th Century History
Piperazines
Pyrimidines
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Antineoplastic Agents
Biomedical Research
Leukemia
Neoplasms
Therapeutics
Imatinib Mesylate

Keywords

  • CML
  • Imanitib
  • Leukemia
  • Molecularly targeted therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Imatinib (Gleevec®) as a paradigm of targeted cancer therapies. / Druker, Brian.

In: Keio Journal of Medicine, Vol. 59, No. 1, 03.2010, p. 1-3.

Research output: Contribution to journalArticle

@article{4164111c9bd842cc94e2964f99cb9caa,
title = "Imatinib (Gleevec{\circledR}) as a paradigm of targeted cancer therapies",
keywords = "CML, Imanitib, Leukemia, Molecularly targeted therapy",
author = "Brian Druker",
year = "2010",
month = "3",
doi = "10.2302/kjm.59.1",
language = "English (US)",
volume = "59",
pages = "1--3",
journal = "Keio Journal of Medicine",
issn = "0022-9717",
publisher = "Keio University School of Medicine",
number = "1",

}

TY - JOUR

T1 - Imatinib (Gleevec®) as a paradigm of targeted cancer therapies

AU - Druker, Brian

PY - 2010/3

Y1 - 2010/3

KW - CML

KW - Imanitib

KW - Leukemia

KW - Molecularly targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=77954302007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954302007&partnerID=8YFLogxK

U2 - 10.2302/kjm.59.1

DO - 10.2302/kjm.59.1

M3 - Article

C2 - 20375651

AN - SCOPUS:77954302007

VL - 59

SP - 1

EP - 3

JO - Keio Journal of Medicine

JF - Keio Journal of Medicine

SN - 0022-9717

IS - 1

ER -